Tirzepatide (Mounjaro®) is a novel dual-action drug combining GIP and GLP-1 receptor agonism to treat Type 2 Diabetes (T2D). Approved by the FDA in 2022, it achieves substantial reductions in both HbA1c and body weight, surpassing results from traditional GLP-1-based treatments. Clinical trials highlight its impact on T2D patients, with the SURPASS-4 study showing lower mortality during COVID-19 when compared to insulin glargine. With a favorable safety profile, Tirzepatide presents a promising, well-tolerated option in the management of complex metabolic conditions, including potential future uses in obesity treatment.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Para Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
